The case tracks the journey of an Indian pharmaceutical firm, Glenmark Pharmaceuticals, which had traditionally focused on generic drugs, in the area of discovery research. A number of Indian firms sought to transfer into discovery research after India entered the international product patent system in 1994 with all the signing of the WTO TRIPs agreement. Glenmark invested heavily in developing its capacities to undertake high-risk pharmaceutical research, and within three years developed several promising molecules.
Organizing for Innovation at Glenmark (A) Case Study Solution
The case scenario takes the students back to year 2008, one of the very critical periods in the development of the company. Three of Glenmark's four drug development projects have failed and the fourth is showing signs of failure. The company's stock price has plummeted as well as the direction is under pressure from financial analysts to drop discovery research and focus on what they had always done best generics. The case places participants in the seat of Glenmark's CEO Glenn Saldanha, who must, for its R&D., develop a future plan of action amid the building pressure and resource constraints on the business to be or not to be the innovation business? That is the question before Saldanha and the classroom.
PUBLICATION DATE: June 30, 2013 PRODUCT #: ISB028-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
David Melcher
General Dynamics and Computer Sciences Corp.: Outsourcing the IS Function (D)
American Barrick Resources Corp.: Managing Gold Price Risk
NEC
France Telecom in 2010
TTTech (A) Seeking Growth and Scale in New and Existing Markets
First Solar, Inc. in 2010
Stanford Hospital and Clinics (A): Building the Business Case for an Electronic Medical Records System
kaChing
User-Generated Content Systems at Intuit (A)
